News

Ad hoc: Medigene announces capital reduction and nomination of new members to a reduced Supervisory Board

Martinsried/Munich, June 5, 2013. Medigene AG (MDG, Frankfurt, Prime Standard) announces today that it will publish its invitation to the annual general meeting, which will be held on 16 July, 2013, in the Federal Gazette on Friday, 7 June 2013. The agenda includes a draft resolution of the Executive and Supervisory Boards on an ordinary reduction of Medigene AG share capital by EUR 29,616,417.00 to EUR 9,872,139.00 by consolidation of the issued no-par value shares in a ratio of 4:1 from 39,488,556 to 9,872,139 shares, pursuant to §§ 222 ff. of the German Stock Corporation Act.

This measure does not affect the value of the company. Being an accounting measure, the reduction will result in a transfer from subscribed capital to capital reserves on the shareholders' equity side of the balance sheet of Medigene AG. Thereby the price of the shares shall be significantly increased above the nominal value of one Euro therefore increasing the transaction capacity of Medigene AG in respect of the minimum issue price according to § 9, par. 1 of the German Stock Corporation Act. However, no specific measures are currently planned.  

Additional agenda items provide for a reduction of the Supervisory Board from six to three members by amendment to the Articles of Incorporation as well as the re-election of the Supervisory Board members. The term of office of all Supervisory Board members ends according to schedule with the close of the annual general meeting on 16 July 2013. The Supervisory Board nominates the following persons for election to the Supervisory Board: Prof. Dr. Horst Domdey, Dave Lemus and Dr. Yita Lee for a period of three years; Prof. Dr. Winnacker, Dr. Werner, and Mr. Kühn until the registration of the above-mentioned amendment to the Articles of Incorporation into the Commercial Register.

Further details are available at the company website.

Contact Medigene AG
Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com